Laryngeal aspergillosis in an acquired immunodeficiency syndrome patient

Aspergillosis is a rare infection. It varies considerably in its virulence depending on whether or not the patient affected is immunodepressed. The serious form is characterized by vascular invasion with haematogenic dissemination, tissue infarction andnecrosis. The most often affected site is the l...

Full description

Saved in:
Bibliographic Details
Published in:Journal of laryngology and otology 1998-05, Vol.112 (5), p.488-490
Main Authors: Delbrouck, C., Chantrain, G., Kampouridis, S., Petein, M.
Format: Article
Language:English
Subjects:
Acquired immunodeficiency syndrome
AIDS-Related Opportunistic Infections - diagnosis
AIDS-Related Opportunistic Infections - drug therapy
AIDS/HIV
Aspergillosis
Aspergillosis - diagnosis
Aspergillosis - drug therapy
Biological and medical sciences
Clinical Records
Ent and stomatologic mycoses
Human mycoses
Humans
Infectious diseases
Laryngeal Diseases - diagnosis
Laryngeal Diseases - drug therapy
Laryngeal Diseases - microbiology
Larynx
Male
Medical sciences
Middle Aged
Mycoses
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Aspergillosis is a rare infection. It varies considerably in its virulence depending on whether or not the patient affected is immunodepressed. The serious form is characterized by vascular invasion with haematogenic dissemination, tissue infarction andnecrosis. The most often affected site is the lung. A laryngeal localization is exceptional and usually results from dissemination from a lower airways portal of entry. Diagnosisis difficult: cultures are only positive in 50 per cent of cases, while in 60 per cent of cases the characteristic histological features reminiscent of sprigs of mistletoe are only found on postmortem examination. In view of the high morbidity and mortality in acquired immunodeficiency syndrome (AIDS) sufferers, this condition must be treated early and aggressively. Treatment is based essentially on amphotericin B and itraconazole.
ISSN:0022-2151
1748-5460
DOI:10.1017/S0022215100140861